Innovations in IVF and assisted reproduction: progress and limitations

In vitro fertilisation (IVF) continues to evolve, but a new technique does not necessarily improve the chance of having a baby. Established methods, additional options still under debate, and research should be distinguished. Their value depends on clinical outcomes and safety, rather than novelty alone.

Artificial intelligence and embryo monitoring

Time-lapse incubators photograph embryos as they develop. Algorithms can help analyse these images and rank embryos. This provides information for embryologists, without guaranteeing better clinical selection. For most patients, the evidence assessed by the HFEA does not show improved chances of a live birth with this technology, including when automated analysis is used.

Egg freezing: preserving a possibility

Vitrification is a rapid egg-freezing technique. It allows eggs to be considered for later use, but not all eggs survive warming and pregnancy is never guaranteed. Outcomes depend particularly on age at collection and the number of eggs available. Dr Krief can provide information about this option; he does not perform egg freezing.

Genetic testing: distinguishing the indications in France

Preimplantation genetic tests are not all equivalent. In France, targeted preimplantation genetic diagnosis may be authorised when there is a high risk of passing on a particularly serious genetic condition considered incurable at diagnosis. The abnormality must have been identified and the case assessed within the applicable framework; some parental chromosomal rearrangements may qualify. Screening for abnormalities in chromosome number, called PGT-A or DPI-A, is not authorised in France. Preimplantation genetic diagnosis is therefore not a routine test for every IVF cycle or miscarriage.

Endometrial receptivity: no routine testing

Receptivity tests such as ERA aim to determine embryo-transfer timing using an endometrial biopsy. Routine use has not demonstrated a benefit for live births. The HFEA even reports a possible reduction in effectiveness for most patients: a transfer described as “personalised” is not automatically more effective.

The microbiome: an area still being assessed

Associations between the microbiome and implantation are being studied. They do not establish that broad screening, or treatment intended to modify the microbiome, improves live birth outcomes. This should be distinguished from targeted assessment for chronic endometritis, which may be considered in selected clinical circumstances.

Stem cells: research rather than an established treatment

Stem cells are being investigated, but ESHRE does not recommend their use to treat ovarian insufficiency or low ovarian reserve. These approaches should not be presented as a proven way to restore fertility.

What should you ask before considering an additional option?

Ask what problem the proposed option aims to address, which studies support its value in your circumstances, and whether the benefit concerns live births rather than an intermediate outcome. Ask about risks, any cost and alternatives. The team should also explain what is routine care and what is research. This article describes techniques; it is not a list of equipment or services available at the practice.